Advertisement
Screener

REPLIGEN CORP (RGEN) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements

2.8 / 5 stars · 68/120 Roast Me

REPLIGEN CORP Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements

REPLIGEN CORP (RGEN) reported Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements of 651.26 thousand shares for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-11-01.

Discontinued › Notes

us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements · last filed 2018-11-01

  • REPLIGEN CORP incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2018-09-30 was 651.26K shares, a 34.49% increase year-over-year.
  • REPLIGEN CORP incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2018-06-30 was 480.56K shares, a 9.86% increase year-over-year.
  • REPLIGEN CORP incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2017-09-30 was 484.24K shares, a 9.27% decline year-over-year.
  • REPLIGEN CORP incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2017-06-30 was 437.43K shares, a 16.81% decline year-over-year.
Period endIncremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 3 monthIncremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 6 monthIncremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 9 month
2018-09-30651.26K shares
10-Q · filed 2018-11-01
511.43K shares
10-Q · filed 2018-11-01
2018-06-30480.56K shares
10-Q · filed 2018-08-02
433.96K shares
10-Q · filed 2018-08-02
2017-09-30484.24K shares
10-Q · filed 2018-11-01
454.34K shares
10-Q · filed 2018-11-01
2017-06-30437.43K shares
10-Q · filed 2018-08-02
433.48K shares
10-Q · filed 2018-08-02
2017-03-31490.62K shares
10-Q · filed 2017-05-04
2016-09-30533.75K shares
10-Q · filed 2017-11-09
526.09K shares
10-Q · filed 2017-11-09
2016-06-30525.83K shares
10-Q · filed 2017-08-03
525.32K shares
10-Q · filed 2017-08-03
2016-03-31468.89K shares
10-Q · filed 2017-05-04
2015-09-30764.56K shares
10-Q · filed 2016-11-03
757.62K shares
10-Q · filed 2016-11-03
2015-06-30800.22K shares
10-Q · filed 2016-08-04
754.15K shares
10-Q · filed 2016-08-04
2015-03-31695.75K shares
10-Q · filed 2016-05-05
2014-09-30650.37K shares
10-Q · filed 2015-11-05
807.01K shares
10-Q · filed 2015-11-05
2014-06-30842.69K shares
10-Q · filed 2015-08-06
865.28K shares
10-Q · filed 2015-08-06
2014-03-31868.18K shares
10-Q · filed 2015-05-08
2013-09-30693.48K shares
10-Q · filed 2014-11-07
699.64K shares
10-Q · filed 2014-11-07
2013-06-30673.46K shares
10-Q · filed 2014-08-11
672.25K shares
10-Q · filed 2014-08-11
2013-03-31614.82K shares
10-Q · filed 2014-05-09
2012-09-30308.21K shares
10-Q · filed 2013-11-08
290.40K shares
10-Q · filed 2013-11-08
2012-06-30303.95K shares
10-Q · filed 2013-08-07
285.05K shares
10-Q · filed 2013-08-07
2012-03-31280.17K shares
10-Q · filed 2013-05-07
2011-09-30137.03K shares
10-Q · filed 2012-11-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
BIO-TECHNE Corp (TECH)United States$11.379B74.68
Twist Bioscience Corp (TWST)United States$11.540B-47.21
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
EXELIXIS, INC. (EXEL)United States$14.358B16.15
Immunovant, Inc. (IMVT)United States$7.028B-14.78